3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms by Site
3
Neoplasms
3
Neoplasms, Glandular and Epithelial
2
Neoplasms by Histologic Type
2
Digestive System Neoplasms
2
Digestive System Diseases
2
Colorectal Neoplasms
2
Thoracic Neoplasms
1
Stomach Neoplasms
1
Respiratory Tract Neoplasms
1
Rectal Diseases
1
Previously Treated Metastatic Colorectal Cancer
1
Pancreatic Neoplasms
1
Pancreatic Diseases
1
Lung Neoplasms
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Colonic Diseases
1
Carcinoma, Pancreatic Ductal
1
Carcinoma, Non-Small-Cell Lung
1
Bronchial Neoplasms
1
Adenocarcinoma
1
Interventions
Carboplatin
5
Pemetrexed
4
pembrolizumab
3
Paclitaxel
3
Gemcitabine
2
Erlotinib Hydrochloride
2
Cisplatin
2
pralsetinib
1
patritumab
1
napabucasin
1
camrelizumab
1
Vinorelbine
1
TNFSF10 protein, human
1
Radiotherapy, Intensity-Modulated
1
Nivolumab
1
Injections
1
Gefitinib
1
Docetaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Thoracic Neoplasms
×
napabucasin
×
Clear all
NCT02826161
2023-11-15
CanStem43L
Sumitomo Pharma America, Inc.
Phase 3
Terminated
4 enrolled
6 charts